logo-loader

Pfizer signs $6bn licensing deal with China’s 3SBio for cancer drug

Published: 08:05 20 May 2025 BST

Pfizer Inc - Pfizer signs $6bn licensing deal with China’s 3SBio for cancer drug

Pfizer Inc (NYSE:PFE, ETR:PFE) has agreed a licensing deal worth up to $6 billion with Chinese biopharmaceutical group 3SBio to develop and commercialise an experimental cancer treatment.

The drug, SSGJ-707, is currently in clinical trials in China for use against lung, colorectal and gynaecological cancers. Under the agreement, 3SBio will receive an upfront payment of $1.25 billion and could earn up to $4.8 billion more through milestone payments.

Pfizer will also invest $100 million in 3SBio via an equity stake. The deal gives 3SBio the rights to commercialise the drug in China, while Pfizer retains global rights.

The announcement sent 3SBio shares up more than 34% in Hong Kong. The move bolsters Pfizer’s oncology portfolio, a key growth area for the company.

FTSE 100 off to a wobbly start; JS Sports slumps as sales come under...

It's been a wobbly start for the FTSE 100, with the blue chip index falling in early trade but breaking a touch higher an hour into the session.It's currently 5 points up at 8,786 - a gain of less than a tenth of a percent.Retailers JD Sports Fashion PLC (LSE:JD.) and Marks and Spencer...

5 minutes ago
OSZAR »